initial guidance about the amount of change associated with improvement or worsening, supporting its use in RA care, research and decision-making.

Acknowledgements: The CATCH study was designed and implemented by the investigators and financially supported through unrestricted research grants from: Amgen and Pfizer Canada - Founding sponsors since January 2007; AbbVie Corporation and Hoffmann-LaRoche since 2011; Medexus Inc. since 2013; Merck Canada since 2017, Sandoz Canada, Biopharmaceuticals since 2019, Gilead Sciences Canada since 2020 and Fresenius Kabi Canada Ltd. since 2021. Previously funded by Janssen Biotech from 2011-2016, UCB Canada and Bristol-Myers Squibb Canada from 2011-2018, Sanofi Genzyme from 2016-2017, and Eli Lilly Canada from 2016-2020.

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2021-eular.1663

POS1460-HPR MYRA TOUCH FOR DISEASE ACTIVITY EVALUATION IN RHEUMATOID ARTHRITIS: A COMPARISON OF PATIENT-REPORTED OUTCOMES WITH PHYSICIAN'S ASSESSMENT

L. H. Eow¹, J. Yew¹, K. H. Lee², S. Selvadurai², S. M. Liao², N. Mohd Noor², A. Mohd², Y. L. Loh², S. C. Gun². ¹Hospital Tuanku Ja'afar, Medical Department, Seremban, Malaysia; ²Hospital Tuanku Ja'afar, Medical Department, Seremban, Malaysia

Background: Patient-reported outcomes (PROs) have become an essential component of patients' assessment in the management of Rheumatoid Arthritis (RA). They have been reported to be at least as informative if not more than physician assessed outcomes.

MyRA Touch was pioneered by the Rheumatology Unit of Hospital Tuanku Ja'afar in Seremban Malaysia in March 2018, to engage and empower all RA patients on their own disease activity monitoring. It is an electronic platform, designed to enhance the application of electronic patient reported outcomes (ePROs) among RA patients where they examine and record their own painful and/or swollen joints for DAS28 calculation and report their health assessment through Routine Assessment of Patient Index Data with 3 Measures (RAPID 3). MyRA Touch is an applications (App) that is user friendly and available in four major spoken languages (English, Chinese, Malay and Tamil) with an animated version for patients who are illiterate.

Objectives: The objectives of this study are to determine the correlation between:

- I) Patient-reported and physician reported DAS28 ESR/CRP
- II) RAPID3 and Clinical Disease activity Index (CDAI)
- III) RAPID3 and DAS28 ESR/CRP assessed by physician and patient
- IV) RAPID3 and inflammatory markers ESR/CRP.

Methods: This was a cross-sectional study carried out in the Rheumatology Unit of Hospital Tuanku Ja'afar. All data entered through MyRA Touch App from April 2018 till April 2020 was analysed.

Results: There were a total of 562 patients who entered the data in the App, 87.9% were women. The ethnic compositions of the study subjects comprised of Indians (36.7%) followed by the Malays (34.7%), Chinese (26.3%) and other ethnicities (2.3%). About half of patients (59.8%) were in the 51-70 age group whereas 22.9%, 1.8% and 15.5% were in the 31-50, 18-30 and above 70 age groups respectively. The majority of our patients (96%) were literate. A total of 54.3% of them received secondary education, 27% primary, 12.2% tertiary and 6.6% did not receive any formal education.

There was a high level of correlation between DAS28 ESR/CRP performed by patient and DAS28 ESR/CRP assessed by physician, ($r=0.808$ for DAS28 ESR and $r=0.804$ for DAS28 CRP). RAPID3 also showed high level of correlation with CDAI and DAS28 CRP assessed by patient ($r=0.700$ and $r=0.718$ respectively). There was a moderate correlation between DAS28 ESR/CRP done by physician with RAPID3 ($r=0.656$ and $r=0.696$ respectively). RAPID3 demonstrated little correlation with inflammatory markers ESR and CRP ($r=0.141$ and $r=0.171$ respectively).

Conclusion: PROs via DAS 28 (ESR/CRP) and RAPID3 showed moderate to high correlation with disease activity assessed by physician. We can empower patients to perform their own disease assessment by using the MyRA Touch App before seeing their physician and the information provided in the App, can help to reduce consultation time. During the COVID-19 pandemic, telemedicine is very much encouraged. By using the MyRA Touch, patients can assess their own tender and swollen joint count on a homunculus, evaluate their own physical function, health and pain using the RAPID3 parameters. The information obtained from the PROs in the MyRA touch App enables the physician to make a more comprehensive virtual assessment of the patient's condition which helps

in treatment decision making. In conclusion, MyRA Touch is an useful tool for disease activity measurement by patient.

REFERENCES:

- [1] Jenny AA, Diana BC, Omar JC, et al. Usefulness of Patients-Reported Outcomes in Rheumatoid Arthritis Focus Group. Hindawi Publishing Corporation Arthritis, vol 2012, Article ID935187.
- [2] Ana MO, Clifton OB. Patient Reported Outcomes in Rheumatoid Arthritis Clinical Trials. Curr Rheumatol Rep. 2015 April;17(4):501.

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2021-eular.1813

POS1461-HPR THE DEVELOPMENT OF A NOVEL EPRO DELIVERY SYSTEM TO MEASURE PATIENT QUALITY OF LIFE IN ROUTINE CLINICAL CARE: AN ANALYSIS OF 5 YEARS OF EXPERIENCE

K. Tymms^{1,2}, T. Smith¹, C. Deakin¹, T. Freeman³, D. Hoffman³, D. Segelov³, H. Griffiths^{1,4}, S. Ciciriello^{1,5}, P. Youssef^{1,6}, D. Mathers^{1,7}, C. Osullivan¹, G. Littlejohn^{1,8}. ¹OPAL Rheumatology, Ltd, Sydney, Australia; ²Canberra Rheumatology, Canberra, Australia; ³Software 4 Specialists (S4S), Pty Ltd, Sydney, Australia; ⁴Barwon Rheumatology, Services, Geelong, Australia; ⁵Dept. of Rheumatology, Royal Melbourne Hospital, Melbourne, Australia; ⁶Dept. of Rheumatology, Royal Prince Alfred Hospital, Sydney, Australia; ⁷Georgetown Arthritis, Georgetown, Australia; ⁸Dept. of Medicine, Monash University, Clayton, Australia

Background: Registry studies and clinical trials are increasingly incorporating patient reported outcomes (PROs) to measure the full burden of disease and better measure the efficacy and value of medicines; however, the burden of paper-based surveys, time constraints, and privacy concerns impede the widespread use of PROs in routine clinical care.

Objectives: To develop a simple and secure technological solution to incorporate validated PROs into routine clinical care for patients with rheumatic diseases, and to assess the patient response to functional assessment of chronic illness therapy fatigue (FACIT-F), patient health questionnaire-2 (PHQ-2), and healthcare resource utilization (HCRU) questionnaires delivered using this ePRO method.

Methods: A novel ePRO questionnaire delivery system was developed by Software4Specialists in partnership with OPAL Rheumatology. Validated PRO questionnaires were sent from the patient's electronic medical record (Audit4, Software4Specialists) and delivered to the patient's email address at time intervals specified by the rheumatologist (defaults to quarterly) or completed in the clinic waiting room prior to the consultation using a tablet or the patient's smart phone (in-practice). Completed questionnaires were encrypted and returned directly to the patient's Audit4 electronic medical record held on the clinician's server for review at the next clinical consultation. The link to the PRO questionnaire expired within 28 days if the questionnaire was not completed, and the questionnaires were automatically cancelled if 2 consecutive links expired. This technology was made available to up to 111 rheumatologists located in 42 clinics in 6 states/territories in Australia, and the use of this technology to furnish the clinical consultation was voluntary for clinicians and patients. Deidentified clinical data was extracted from the servers of participating rheumatologists and aggregated across all sites.¹ Data collected between April 2016-Dec 2020 was analysed descriptively.

Results: Between April 2016-Dec 2020, 99,505 FACIT-F, PHQ-2 and HCRU questionnaires have been delivered to 5,784 patients from 39 of 42 contributing clinics (93%). 85% of questionnaires were delivered via email and 15% in-practice. Overall, 85% of patients completed at least one questionnaire, and of all questionnaires sent, 73% were completed. These rates have remained consistent over time. The completion rates were higher when questionnaires were delivered to patients in-practice compared to email (96% vs 69%). Females were more likely to engage with the questionnaires than males (87% vs 81%), and older patients were slightly more likely to complete all questionnaires delivered. 69% of questionnaires sent via email were completed on the day they were delivered and 94% were completed within 7 days. The median (IQR) number of questionnaires completed per patient was 3 (1,7) and the median (IQR) time since the first questionnaire was completed was 13 months (5,26).

Conclusion: The novel Audit4 ePRO delivery system is an effective tool for incorporating PROs into routine clinical care to capture data directly from the patient on the impact of their condition on their quality of life. The data generated provides a unique opportunity to understand the full burden of disease for patients in the real-world setting and the impact of interventions.